Skip to main content
. 2020 Nov 22;73(1):143–150. doi: 10.1002/art.41489

Figure 1.

Figure 1

Distribution of patients with primary Sjögren’s syndrome to the randomized treatment groups, with follow‐up. Two subjects did not meet the eligibility criterion requiring serum positivity for anti‐Ro autoantibodies. Eligible patients were randomized to receive RSLV‐132 (10 mg/kg) or placebo, once weekly for 2 weeks and then every 2 weeks for 12 weeks.